Consensus Telix Pharmaceuticals Limited

Stocks

TLX

AU000000TLX2

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 11:41:42 17/07/2026 am IST			5-day change	1st Jan Change
14.91 ^AUD	-4.48%		-8.36%	+33.12%

03:59pm	RBC Downgrades Telix Pharmaceuticals to Sector Perform From Outperform, Keeps AU$18 Price Target	MT
06:16am	Telix Pharmaceuticals Completes Phase Three Enrollment for Prostate Cancer Imaging Study in Japan	MT

Evolution of the Average Target: Telix Pharmaceuticals Limited

Evolution of the Target Price: Telix Pharmaceuticals Limited

Changes in Analyst Recommendations: Telix Pharmaceuticals Limited

7fa182a69e360.LJkfswGwIeimSiNELMUaw-ywa_SNsFFoeg4JRhkBrNw.X_BX22LRTaTuOEgLWYpRp9mBPpzM0jY4EVdrKStpm718q33LMcMQh9wBdg~ac1981f10f90f65a1f1854e3e7271d0c

Analysts' recommendations: Telix Pharmaceuticals Limited

03:59pm	RBC Downgrades Telix Pharmaceuticals to Sector Perform From Outperform, Keeps AU$18 Price Target	MT
03/07	Telix Pharmaceuticals Securing FDA Nod in Line With Expectations, Says Jefferies, Shares Down 3%	MT
16/04	Telix Enters Attractive Market With Late-Stage Brain Cancer Drug Trial in US, Jefferies Says	MT
13/04	Telix Pharmaceuticals' Pipeline Validated by Regeneron Deal, Citi Says	MT
08/04	Jarden Adjusts Telix Pharmaceuticals's Price Target to AU$21.80 from AU$21, Keeps at Buy	MT
08/04	Telix Pharmaceuticals US PSMA PET Sales Gain Traction, Seen to Grow Market Share, Says Jefferies	MT
02/03	Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says	MT
21/01	Telix Pharmaceuticals Poised for Growth With Strong Illuccix Sales, Gozellix Launch, Jefferies Says	MT
14/01	Telix Pharmaceuticals Reaffirms Guidance Amid Imminent Drug Launches in US, Says Jefferies	MT
12/12	Telix Pharmaceuticals Poised for 'Solid' Q4 Revenue Growth, Jefferies Says	MT
12/11	Alerts from law firm on Telix pharmaceuticals withdrawn	RE
12/11	Telix Reports Positive Results from TLX250-CDx Imaging Trial in Triple Negative Breast Cancer Patients, Shares Fall 3%	MT
07/25/07	Barrenjoey Markets Starts Telix Pharmaceuticals at Overweight with AU$22 Price Target	MT
25/25/25	Telix Pharmaceuticals' Gozellix Expected to See Strong Sales Growth After TPT Status Grant, Jarden Research Says	MT
23/25/23	UBS Adjusts Price Target on Telix Pharmaceuticals to $20 From $23, Maintains Buy Rating	MT
19/25/19	Telix Pharmaceuticals Shows Strong Growth Potential With Blockbuster Drug Prospect, Citi Says	MT
18/25/18	Citigroup Initiates Telix Pharmaceuticals at Buy With $22 Price Target	MT
21/25/21	Telix Pharmaceuticals' Profitability Expected to Rebound, Wedbush Says	MT
06/25/06	Jarden Research Adjusts Telix Pharmaceuticals' Price Target to AU$27.61 from AU$29.14; Keeps at Buy	MT
03/25/03	HC Wainwright Initiates Telix Pharmaceuticals at Buy With $23 Price Target	MT
05/25/05	Wedbush Initiates Telix Pharmaceuticals at Outperform With $22 Price Target	MT
27/25/27	UBS Adjusts Price Target on Telix Pharmaceuticals to $22 From $21, Keeps Buy Rating	MT
30/24/30	Telix Pharmaceuticals Has Long-term Opportunity to Become Isotope Manufacturer After Acquisition, Says Jefferies	MT
23/24/23	Bell Potter Downgrades Telix Pharmaceuticals to Hold From Buy; Price Target is AU$21.30	MT
30/24/30	Jarden Research Adjusts Telix Pharmaceuticals' Price Target to AU$22.55 From AU$22.49, Keeps at Buy	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	TELIX PHARMACEUTICALS LIMITED					+49.59%
	LONZA GROUP AG					+16.35%
	REVOLUTION MEDICINES, INC.					+11.9%
	BEONE MEDICINES AG					+30.69%
	IQVIA HOLDINGS INC.					+10.22%
	CELLTRION, INC.					+46%
	ASCENDIS PHARMA A/S					+16.1%
	MEDPACE HOLDINGS, INC.					-12.19%
	EUROFINS SCIENTIFIC SE					+2.2%
	ICON PUBLIC LIMITED COMPANY					+6.95%
	Average					+17.78%
	Weighted average by Cap.					+17.52%